TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02394483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments
Study: NCT02887534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-low dose
Description: SPARC1401- low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-mid dose
Description: SPARC1401- mid dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-high dose
Description: SPARC1401-high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference1401 (Tizanidine)
Description: Reference1401 (Tizanidine) three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo1401
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo1401
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo1401
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo1401
Description: Placebo
Study: NCT02824380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 H
Description: 5% minoxidil / high dose of finasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 H
Description: 5% minoxidil / high dose of finasteride
Study: NCT02394483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments
Study: NCT02824380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 L
Description: 5% minoxidil / low dose of finasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 L
Description: 5% minoxidil / low dose of finasteride
Study: NCT03013777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week CBT Program
Study: NCT02973581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
Study: NCT02446457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04503421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
Study: NCT00636337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: Computer program training for attention difficulties.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison computer program
Study: NCT02394483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments
Study: NCT02973581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study: NCT03627468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 5%
Description: Sofpironium Bromide Gel, 5%
Study: NCT02973581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study: NCT03627468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Sofpironium Bromide Gel, 15%
Study: NCT02973581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
Study: NCT01257581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: creatine
Description: creatine monohydrate powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen citrate capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen citrate capsules
Study: NCT01094262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR (standard pain medication)
Description: Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
Study: NCT06076941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated.
Study: NCT02389595

Intervention type: OTHER
Intervention: HIV positive subjects
Description: This group will provide a blood sample.

Intervention type: OTHER
Intervention: Non-infected control subjects
Description: This group will be de-identified blood samples from a commercial source.
Study: NCT02963064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Description: Procedure: single intravenous infusion of JSP191 antibody
Study: NCT00964353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
Study: NCT04149535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel® Cerebral Protection System
Description: cerebral embolic protection system
Study: NCT02682550

Intervention type: PROCEDURE
Intervention: blood drawing
Description: blood drawing

Intervention type: PROCEDURE
Intervention: blood drawing
Description: blood drawing
Study: NCT01737255

Intervention type: OTHER
Intervention: Whole body MRI
Description: Individuals will undergo whole body and brain MRI

Intervention type: OTHER
Intervention: Whole body MRI
Description: Individuals will undergo whole body and brain MRI
Study: NCT02394483

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics
Study: NCT04596800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program + Enhanced Recovery After Surgery
Description: Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgery
Description: ERAS
Study: NCT03331250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
Study: NCT02635763

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve and the lateral cutaneous nerve block
Description: Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar plexus and sacral plexus nerve block
Description: Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
Study: NCT00502944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor-based HIV screening
Description: Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emergency staff member-based HIV screening
Description: Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
Study: NCT00417118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant
Description: oral administration (capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: oral administration (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration (capsules)
Study: NCT01736124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized cognitive training
Description: A variety of computer games tailored to address their personal cognitive deficits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control games
Description: A variety of computer games that are engaging but not designed to enhance cognitive skills
Study: NCT03553927

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Energy Diet
Description: Caloric restriction to achieve weight loss

Intervention type: OTHER
Group type: OTHER
Intervention: NHS advice on healthy eating
Description: Advice on energy requirements as per the British Dietetic Association
Study: NCT00646789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0633
Description: patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
Study: NCT04908709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo sMRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo sMRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Target volume treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proton Therapy
Description: Target volume treatment
Study: NCT03630042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV dose given on day 1 of a three week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV dose given up to 8 times in the trial
Study: NCT01135290

Intervention type: DRUG
Group type: OTHER
Intervention: Aquaphor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP828-101
Study: NCT03779958

Intervention type: OTHER
Intervention: Mobile App
Description: a mobile app that demonstrates hand therapy exercises
Study: NCT02634749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic introduction of taste portions
Description: A systematic introduction of plant foods from the Nordic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein reduced complementary foods
Description: Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic diet
Description: Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
Study: NCT04966052

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05055739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid plate X steel wires
Description: Compare the sternal alignment between the fixation with rigid plate X steel wires.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid plate X steel wires
Description: Compare the sternal alignment between the fixation with rigid plate X steel wires.
Study: NCT01097330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
Study: NCT00769704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
Study: NCT02715401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303
Study: NCT00769704

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 125 µg/m² subcutaneous injection
Study: NCT00326014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Glaucoma Surgery
Study: NCT02715401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Study: NCT00483262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Description: Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
Study: NCT01855308

Intervention type: PROCEDURE
Intervention: Single site robotic chole
Description: Cholecystectomy

Intervention type: DEVICE
Intervention: da Vinci Si Surgical System
Description: minimally invasive robotic surgical system designed to facilitate complex procedures
Study: NCT00601640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Na gel
Description: Given topically twice daily on days 1-90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Na gel
Description: Given topically twice daily on days 1-90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine HCL ointment
Description: Given topically twice daily on days 1-90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine HCL ointment
Description: Given topically twice daily on days 1-90
Study: NCT02359058

Intervention type: DRUG
Group type: OTHER
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Administered IV
Study: NCT03354533

Intervention type: DRUG
Group type: OTHER
Intervention: L-fucose
Description: Oral ORL-1F
Study: NCT02836678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ridge splitting, immediate implant, Nanobone with PRF.
Description: * Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ridge splitting, immediate implantand PRF.
Description: * Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue).